Home Introduction Divisions Organized Research Units Research Training Program Selected Scholarly Interests

Patricia W. Finn, MD. Department Chair

© Copyright 2014 The Board of Trustees of the University of Illinois

Robert A. Winn, M.D.

Academic Title: Professor of Medicine

Administrative Positions: Associate Vice President for Health Affairs; Director, Lung Cancer Program, University of Illinois Hospital & Health System

Division: Pulmonary, Critical Care, Sleep and Allergy Medicine

Location: 914 S. Wood St., MCA (MC 973), Chicago, IL 60612

Phone: (312)355-1179 (Office) Fax: (312)413-3099



MD, University of Michigan Medical School, Ann Arbor, MI (1993)

Intern, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL (1993-1994)

Resident, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL (1994-1997)

Fellow, University of Colorado Health Sciences Center, Denver, CO (1997-2000)

Faculty Positions:

Clinical Specialties

Research Interests

Selected Publications

  1. Nemenoff RA, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya RS, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW and Keith RL. Prostacyclin prevents Murine Lung Cancer Independent of the Membrane Receptor by activation of PPAR gamma. Cancer Prev. Res.  1(5);349-356, 2008.
  2. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE and Nemenoff RA. Oncogenic K-Ras Regulates Proliferation and Cell Junctions in Lung Epithelial Cells Through Induction of COX-2 and Activation of MMP-9. Mol. Biol. Cell. 20(3):791-800, 2009.
  3. Weiser-Evans MC, Wang XQ, Amin J, Van Putten V, Choudhary R, Winn RA, Scheinman R, Simpson P, Geraci MW and Nemenoff RA. Depletion of Cytosolic Phospholipase A2 in Bone Marrow-Derived Macrophages Protects against Lung Cancer Progression and Metastasis. Cancer Res. 69(5):1733-8, 2009.
  4. Van Scoyk M, Tennis M and Winn RA. Prostacyclin and Lung Cancer.  Transl. Res. 155(2):57-61, 2010.
  5. Choudhary R, Li  H, Winn RA, Weiser-Evans M and  Nemenoff R. Peroxisome Proliferator-Activated Receptor-γ(PPAR) Inhibits Transformed Growth of Non-Small Cell Lung Cancer Cells Through Selective Suppression of Snail. Neoplasia. 12(3):244-53, 2010.
  6. Tennis M, Van Scoyk M, Heasley L, Vandervest K, Weiser-Evans M, Freeman S, Keith R, Simpson P, Nemenoff R and Winn RA. Prostacyclin Inhibits Non Small Cell Lung Cancer Growth by a Frizzled 9 Dependent Pathway that is blocked by Secreted Frizzled Related Protein 1. Neoplasia. 12(3):224-34, 2010.
  7. Tennis M, Van Scoyk M, Freeman S, Vandervest K, Nemenoff R and Winn RA. Sprouty-4 inhibits transformed cell growth, migration and invasion, and EMT and is regulated by Wnt 7A through PPAR in Non-Small Cell Lung Cancer. Mol. Cancer Res. 8(6):833-43, 2010.
  8. Mueller S, Winn R, Macht M, Fish D, Kiser T and MacLaren R. Neuromuscular blockade resistance during therapeutic hypothermia. Ann. Pharmacother. 45(3): e15, 2011.
  9. Winn, RA and Tuder R. “Un-Slugging” resistance to epidermal growth factor receptor growth factor inhibition: A Positve Outlook for the Future of Lung Cancer Therapy. Am. J. Respir. Crit. Care Med. 183(8):970-2, 2011.
  10. Weekes C and Winn RA. The Many Faces of Wnt and Pancreatic Ductal Adenocarcinoma Oncogenesis. Cancers. 3(3), 3676-3686, 2011.
  11. Tennis MA, VanScoyk MM, Wilson LA, Kelley N and Winn RA. Methylation of Wnt7a is modulated by DNMT1 and tobacco carcinogens in non-small cell lung cancer. PLoS One. 7(3):e32921, 2012.
  12. Tennis MA, Vanscoyk M, Freeman S and Winn RA. Promoter hypermethylation leads to loss of wnt7a in non-small cell lung cancer. Proc. Am. Thorac. Soc. 9(2):83-4, 2012.
  13. Weekes C, Song D, Arcaroli J, Rubio-Viqueira B, Ciobanu M, Cusatis G, Garrett-Maye ER, Winn RA, Messersmith W and Hidalgo M. Stromal Cell-Derived Factor-1 Mediates Resistance to mTOR-directed Therapy in Pancreatic Cancer. Neoplasia. 14(8):690-701, 2012.
  14. Bikkavilli RK, Avasarala S, Vanscoyk M, Sechler M, Kelley N, Malbon CC and Winn RA.  Dishevelled 3 is a novel arginine methyl transferase substrate. Sci. Rep. 2:805, 2012.